Table 1

- Baseline patients’ demographic and disease characteristics (N=199).

Baseline demographicsTotalDVS (n=75)NB (n=64)VBS (n=60)
n (%)
Male134 (67.3)44 (58.6)30 (46.8)60 (100)
Age at presentation (month)
Median (range)24 (192)48 (192)24 (168)9 (156)
Min (max)0.024 (192)0.024 (192)0.024 (168)0.024 (156)
Mean±SD43.9±49.660.1±6.3243.5±6.2124.1±4.37
Age at last follow-up (month)
Median (range)108 (252)120 (252)120 (238)88 (192)
Min (max)12 (264)12 (264)14 (252)12 (204)
Mean±SD114.7±65.2124.9±8.5122.1±7.794.0±6.7
Follow-up duration by month median (range)72 (180)72.0 (156)72.0 (180)78.0 (144)
Groups of age at presentation
Infancy up to 1 year91 (45.7)25 (33.3)30 (46.9)36 (60.0)
Toddler (1-5 years)52 (26.1)20 (26.7)17 (26.6)15 (25.0)
School age (5-16 years)56 (28.1)30 (40.0)17 (26.6)9 (15.0)
Categories of management
Category 162 (31.2)25 (33.3)14 (21.9)23 (38.3)
Category 250 (25.1)15 (20.0)19 (29.7)16 (26.7)
Category 325 (12.6)11 (14.7)4 (6.3)10 (16.7)
Category 462 (31.2)24 (32.0)27 (42.2)11 (18.3)
Surgical intervention
Negative112 (56.3)40 (53.3)33 (51.6)39 (65.0)
Positive87 (43.7)35 (46.7)31 (48.4)21 (35.0)
Surgical intervention types
Vesicostomy40 (20.1)16 (21.3)10 (15.6)14 (23.3)
Iliocystoplasty33 (16.5)14 (18.7)14 (21.9)5 (8.3)
Ureterostomy20 (10.0)9 (12.0)9 (14.1)2 (3.3)
Botox4 (2.0)1 (1.3)3 (4.7)0 (0.0)
Mitrofanoff/monti6 (3.0)3 (4.0)1 (1.6)2 (3.3)
  • DVS: dysfunction voiding syndrome, NB: neurogenic bladder 2ry to spinal lesion, VBS: valve bladder syndrome, SD: standard deviation, Max: maximum, ESKD: end stage kidney disease, Botox: botulinum toxin injection into the bladder wall, Mitrofanoff: appendicovesicostomy, Monti: ileovesicostomy. Category 1: 62 children who did not need CIC or surgery, Category 2: 50 children who needed CIC but did not need surgery, Category 3: 25 children who have surgery but they did not need CIC. Category 4: 62 children who did need both CIC and surgery, CIC: clean intermittent catheterization